Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

What Boosts Adherence to GLP-1s?

GLP-1s sometimes cause unpleasant side effects that can lead to nonadherence and discontinuation, but some patients stay the course anyway. What factors motivate them not to give up?

Big Breakfast Alters Appetite, Gut Health

Breakfast meals higher in protein promote feelings of satiety, and those higher in fiber boost beneficial gut microbiota — both lead to weight loss and metabolic benefits.

Diabetes and Mental Health Care Gaps Exposed

A national investigation has found that gaps between diabetes and mental health services are exposing insulin-treated adults to avoidable harm and death.

US FDA Approves Eton's Liquid Therapy for Rare Water-balance Disorder

The U.S. Food and Drug Administration on Wednesday approved Eton Pharmaceuticals' first-of-its-kind liquid therapy for a ⁠rare hormonal disorder, offering a more precise...

Nearly a Third of US Youth Have Prediabetes or Diabetes

Nearly 1 in 3 US adolescents have prediabetes or type 2 diabetes, with abdominal adiposity being the strongest independent predictor, analysis of national survey data from 2021 to 2023 shows.

Gut Flora May Be Altered by Oral Semaglutide Additive

Salcaprozate sodium, the absorption-enhancing ingredient used in oral semaglutide, is associated with changes in gut microbiota and inflammatory markers in a preclinical study.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

GLP-1s sometimes cause unpleasant side effects that can lead to nonadherence and discontinuation, but some patients stay the course anyway. What factors motivate them not to give up?

Breakfast meals higher in protein promote feelings of satiety, and those higher in fiber boost beneficial gut microbiota — both lead to weight loss and metabolic benefits.

A national investigation has found that gaps between diabetes and mental health services are exposing insulin-treated adults to avoidable harm and death.

The U.S. Food and Drug Administration on Wednesday approved Eton Pharmaceuticals' first-of-its-kind liquid therapy for a ⁠rare hormonal disorder, offering a more precise...

Nearly 1 in 3 US adolescents have prediabetes or type 2 diabetes, with abdominal adiposity being the strongest independent predictor, analysis of national survey data from 2021 to 2023 shows.

Salcaprozate sodium, the absorption-enhancing ingredient used in oral semaglutide, is associated with changes in gut microbiota and inflammatory markers in a preclinical study.

News All Time

Most Americans With Obesity Perceive Just Having Overweight

Experiences of stigma and bias vary across ethnic and racial groups.

Novo Nordisk to Halve US List Price Of Wegovy From 2027

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year to $675 a ⁠month, the Danish...

SARS-CoV-2 Infection Linked to Higher Thyroid-Disease Risk

An analysis of medical records from a hospital system in the Bronx, New York, adds to findings linking SARS-CoV-2 infection to later diagnosis of thyroid conditions.

Intermittent Fasting Offers No Clear Advantage

Analysis of 22 randomized trials finds intermittent fasting produces modest weight loss comparable to standard calorie-restricted diets and shows no clear quality-of-life benefit.

When Heavy or Light Periods Signal Reproductive Risk

Heavy or scant menses often reflect ovulatory, uterine, or hormonal disorders that can indirectly impair conception; targeted evaluation identifies treatable causes to protect fertility.

Novo Nordisk's CagriSema Trial Deals Blow in Obesity Drug Battle With Eli Lilly

Novo Nordisk's next-generation obesity drug CagriSema underperformed Eli Lilly's Zepbound in a head-to-head trial, the Danish drugmaker said on Monday, as it suffered a...

SGA Children on Growth Hormone Show Impaired Metabolism

Children born small for gestational age vs those with isolated growth hormone deficiency have impaired glucose-insulin metabolism, which worsens during growth hormone therapy.

Chan Zuckerberg Initiative Bets on Human Cell Atlas

Backed by multibillion-dollar funding, the initiative scales computing power and cell mapping to accelerate therapy discovery and immune system modelling.

Tirzepatide Now Available in Multi-Dose KwikPen

Patients who pay cash can get the multi-dose KwikPen device on LillyDirect, with prices starting at $299 for the lowest dose.

PFAS Exposure Linked to Higher Gestational Diabetes Risk

The largest meta-analysis yet conducted on the topic suggests that PFAS “forever chemicals” increase the risk for gestational diabetes, highlighting the need for exposure reduction and patient counseling.

Supportive vs Flat Flexible Shoes: No Hip OA Pain Difference

The use of stable supportive shoes does not reduce 6‑month walking hip pain in adults with chronic hip osteoarthritis more than the use of flat flexible ones, according to a randomized clinical trial.

Federal Health Data is Back Online, But Docs Still Skeptical

Information has been restored after the federal government took health information and data websites offline last year - but some physicians say their trust is shaken.

New Intervention Bests Cutting Calories for Weight Loss

Women with obesity can lose more weight with a novel multicomponent nutrition intervention called NutrirCom than on a calorie-restricted diet.

Energy Deficit and Bone Loss in Female Athletes

Social media may glamorize athletes’ diets, but restrictive eating combined with intense training can produce low energy availability, menstrual dysfunction, and bone loss in female competitors.

Why Obesity Research Is Far From Over

Clinicians warn that GLP-1 treatment often ends within a year and can lead to rapid weight regain; experts urge personalized nutrition, behavioral care, and continued research.

What Nutrients Are GLP-1 Users Lacking?

In adults with obesity and/or type 2 diabetes, GLP-1 therapy may lead to nutritional imbalances, with growing evidence indicating depletion of vitamin D, iron, and the B vitamin complex.

Recommended News For You

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

unhealthy sleeping habits and the risk of esophageal adenocarcinoma.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

Mezigdomide Combinations Show Promise in Multiple Myeloma

More nonsmokers are getting lung cancer: Oncologist explains why

The most precise research tools for the deadliest blood cancer have been developed.

Recommended Articles For You

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing 

The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options  

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025 

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

2.

A new theranostic drug targets different cancer types.

3.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

4.

Investigations may result in novel combination therapies for early-stage lung cancers.

5.

A better option for mild to moderate depression?

1.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

2.

Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression

3.

Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma

4.

Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma

5.

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XVI

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

3.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot